Genetic and epigenetic aberrations of CDKN2A lead to enhanced carcinogenesis and poor prognosis in various cancer types including lymphoma, skin cancer, ovarian cancer, and prostate cancer.19 Here, CDKN2A is linked to prostate carcinoma.